👉  VERU is TODAY’S #1 ALERT 👈

Hey Folks, Jeff Bishop here.

The trade war drama continued yesterday with an appeals court reinstating President Trump’s “reciprocal tariffs” at least temporarily while it considers the administration’s appeal.

But as trade advisor Peter Navarro said yesterday afternoon, “Even if we lose, we will do it another way.”

The blockbuster NVDA earnings were still enough to power the major indexes slightly higher yesterday, but I’m pleased to say the stock I alerted you to yesterday morning far outpaced them…

It powered almost 20% higher in the AM and ultimately closed the day in double-digit territory:

Today, I’m taking aim at another small stock that’s riding some very trendy waves.

Have a look at Veru Inc. (VERU) on your preferred trading platform.

The stock has largely been cruising along following the sale of one of its business arms in January, but what interests me most are its recent spikes.

At the start of April, the stock had a 49% runup in two days…

And just on Wednesday, it spiked 31% in a single day after it released some very promising safety data from its clinical trial.

The stock fell back to earth from there, but I’m wondering whether that was due to some key investors taking their winnings.

The company has great prospects, and I see the stock is ticking back up in the pre-market this morning.

I’m watching VERU today to see if the downtick was a blip and if we get a big rally day today.

👉  VERU is TODAY’S #1 ALERT 👈

Here are the 5 things I found most intriguing about VERU:

1. Enobosarm: The Muscle-Preserving Weight Loss Ally 💪🔥

VERU’s lead candidate, enobosarm, is making waves in the weight loss arena. 

As I’m sure you know, GLP-1 drugs like Ozympic and Wegovy are all the rage in the weight loss space. Their most notable downside, though, is the potential to cause muscle loss.

Enobosarm is designed to selectively target fat while preserving lean muscle. It is a novel, oral selective androgen receptor modulator (SARM) of the sort that’s been popular among bodybuilders for a long time now.

On Wednesday, the company released positive topline results from its Phase 2b QUALITY study showcasing a positive safety profile for patients on enobosarm combined with semaglutide (the active ingredient in Ozympic).

Thus far, the study has found that this combo actually led to fewer gastrointestinal side effects compared to semaglutide alone.

This follows earlier results “indicating that enobosarm can selectively enhance fat loss while preserving lean mass and physical function in older patients using semaglutide for weight loss.”

In the placebo + semaglutide group, 32% of weight loss was from lean mass and 68% was from fat. But in the enobosarm 3mg + semaglutide group, it was 0.9% from lean mass and 99.1% from fat. That’s huge!

VERU has requested an End of Phase 2 meeting with FDA which it expects will take place in Q3 2025 in anticipation of its planned Phase 3 clinical program.

2. Sabizabulin: Tackling Inflammation in Heart Disease ❤️🛡️

Separately, the company is taking aim at atherosclerotic coronary artery disease (CAD) — the leading cause of mortality worldwide — with Sabizabulin, an oral microtubule disruptor with broad anti-inflammatory properties. 

Its purpose is to slow or reverse plaque buildup in arteries.

VERU had a pre-IND meeting with the FDA in December 2024, wherein the FDA requested chronic nonclinical toxicology animal studies of Sabizabulin.

By the first half of 2026, the company expects the studies will be completed and it will have submitted a new IND for the proposed indication.

3. Strategic Shift to High-Impact Therapeutics 🔄🎯

VERU has transitioned from its earlier focus on sexual health products to prioritizing treatments for cardiometabolic and inflammatory diseases. 

Specifically, announced the sale of its FC2 Female Condom business in January 2025 for $18 million to allow it to focus on its biopharma pipeline.

This strategic pivot aligns with pressing global health challenges, positioning the company in high-demand therapeutic areas.

4. Strong Institutional Backing 🏦📈

Despite being a smaller player, VERU boasts significant institutional investment. 

Major firms like BlackRock and Vanguard hold substantial shares, indicating confidence in VERU‘s potential. 

BlackRock is sitting on 8.65M shares (5.9% of outstanding VERU shares) and Vanguard is holding 6.25M shares (4.26%) as of March 31.

5. Potential for Significant Upside 🚀📊

Analysts see considerable upside in VERU:

With yesterday’s closing price at $0.51, most of these forecasts suggest multibagger potential. 

This optimism stems from the promising clinical data and the company’s focus on high-impact treatments.

Final Thoughts

VERU is carving a niche in the biopharmaceutical landscape with its innovative approaches to weight loss and cardiovascular health. 

As you do your own research, definitely check out the company’s website, including its recent press releases, as well as this investor presentation released last month.

And of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Awareness Consulting Network for advertising Veru, Inc for a one day marketing program on May 30, 2025. It might seem obvious, but while our client claims not to own any shares in Veru, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Veru, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.